These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27975196)

  • 1. Economic Studies in Motor Neurone Disease: A Systematic Methodological Review.
    Moore A; Young CA; Hughes DA
    Pharmacoeconomics; 2017 Apr; 35(4):397-413. PubMed ID: 27975196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK.
    Tavakoli M; Malek M
    J Neurol Sci; 2001 Oct; 191(1-2):95-102. PubMed ID: 11676998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review.
    Stewart A; Sandercock J; Bryan S; Hyde C; Barton PM; Fry-Smith A; Burls A
    Health Technol Assess; 2001; 5(2):1-97. PubMed ID: 11809124
    [No Abstract]   [Full Text] [Related]  

  • 4. Systematic review of the impact of urinary tract infections on health-related quality of life.
    Bermingham SL; Ashe JF
    BJU Int; 2012 Dec; 110(11 Pt C):E830-6. PubMed ID: 22816657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riluzole for motor neurone disease. Large, more economical trial is needed.
    Wheatley K; Gray R
    BMJ; 2001 May; 322(7297):1305. PubMed ID: 11403061
    [No Abstract]   [Full Text] [Related]  

  • 6. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole.
    Thakore NJ; Pioro EP; Udeh BL; Lapin BR; Katzan IL
    Value Health; 2020 Dec; 23(12):1543-1551. PubMed ID: 33248509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic literature review of health state utility values in head and neck cancer.
    Meregaglia M; Cairns J
    Health Qual Life Outcomes; 2017 Sep; 15(1):174. PubMed ID: 28865475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are adverse effects incorporated in economic models? An initial review of current practice.
    Craig D; McDaid C; Fonseca T; Stock C; Duffy S; Woolacott N
    Health Technol Assess; 2009 Dec; 13(62):1-71, 97-181, iii. PubMed ID: 20018146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
    Hawton A; Shearer J; Goodwin E; Green C
    Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002).
    Zoing MC; Burke D; Pamphlett R; Kiernan MC
    J Clin Neurosci; 2006 Jan; 13(1):78-83. PubMed ID: 16410201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review.
    Di Tanna GL; Bychenkova A; O'Neill F; Wirtz HS; Miller P; Ó Hartaigh B; Globe G
    Pharmacoeconomics; 2019 Mar; 37(3):359-389. PubMed ID: 30596210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of health states in chronic kidney disease: a structured review of the literature.
    Dale PL; Hutton J; Elgazzar H
    Curr Med Res Opin; 2008 Jan; 24(1):193-206. PubMed ID: 18039434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access to palliative care for people with motor neurone disease in New Zealand: a patient's perspective.
    Williams B
    N Z Med J; 2005 Oct; 118(1224):U1711. PubMed ID: 16258583
    [No Abstract]   [Full Text] [Related]  

  • 20. Health Utilities and Costs for Motor Neurone Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2019 Nov; 22(11):1257-1265. PubMed ID: 31708062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.